Rowland Charles A.'s most recent trade in Generation Bio Co was a trade of 53,475 Common Stock done . Disclosure was reported to the exchange on Feb. 9, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Generation Bio Co | Charles A. Rowland | Director | 09 Feb 2026 | 53,475 | 0 | - | - | Common Stock | ||
| Generation Bio Co | Charles A. Rowland | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Feb 2026 | 6,000 | 0 | - | - | Stock Option (right to buy) | |
| Generation Bio Co | Charles A. Rowland | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Feb 2026 | 5,200 | 0 | - | - | Stock Option (right to buy) | |
| Generation Bio Co | Charles A. Rowland | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Feb 2026 | 4,246 | 0 | - | - | Stock Option (right to buy) | |
| Generation Bio Co | Charles A. Rowland | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Feb 2026 | 3,000 | 0 | - | - | Stock Option (right to buy) | |
| Generation Bio Co | Charles A. Rowland | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Feb 2026 | 2,500 | 0 | - | - | Stock Option (right to buy) | |
| Generation Bio Co | Charles A. Rowland | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Feb 2026 | 1,920 | 0 | - | - | Stock Option (right to buy) | |
| Generation Bio Co | Charles A. Rowland | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Feb 2026 | 1,500 | 0 | - | - | Stock Option (right to buy) | |
| Viking Therapeutics Inc | Charles A. Rowland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 20,400 | 20,400 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Charles A. Rowland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 3,150 | 33,150 (0%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Charles A. Rowland | Director | Sale of securities on an exchange or to another person at price $ 35.57 per share. | 27 Oct 2025 | 60,000 | 30,000 (0%) | 0% | 35.6 | 2,134,278 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Charles A. Rowland | Director | Grant, award, or other acquisition of securities at price $ 4.88 per share. | 27 Oct 2025 | 22,000 | 90,000 (0%) | 0% | 4.9 | 107,360 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Charles A. Rowland | Director | Grant, award, or other acquisition of securities at price $ 5.80 per share. | 27 Oct 2025 | 22,000 | 68,000 (0%) | 0% | 5.8 | 127,600 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Charles A. Rowland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Oct 2025 | 22,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Charles A. Rowland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Oct 2025 | 22,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Charles A. Rowland | Director | Grant, award, or other acquisition of securities at price $ 4.48 per share. | 27 Oct 2025 | 16,000 | 46,000 (0%) | 0% | 4.5 | 71,680 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Charles A. Rowland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Oct 2025 | 16,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Generation Bio Co | Charles A. Rowland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Viking Therapeutics Inc | Charles A. Rowland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 18,800 | 18,800 | - | - | Stock Option (Right to Buy) | |
| Generation Bio Co | Charles A. Rowland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Viking Therapeutics Inc | A. Charles Rowland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 32,000 | 32,000 | - | - | Stock Option (Right to Buy) | |
| Generation Bio Co | Rowland Charles A. | Director | Purchase of securities on an exchange or from another person at price $ 1.31 per share. | 01 Dec 2023 | 192,960 | 384,757 | - | 1.3 | 252,778 | Common Stock |
| Generation Bio Co | Charles A. Rowland | Director | Purchase of securities on an exchange or from another person at price $ 1.50 per share. | 01 Dec 2023 | 150,000 | 534,757 | - | 1.5 | 225,000 | Common Stock |
| Generation Bio Co | Charles A. Rowland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Viking Therapeutics Inc | Charles A. Rowland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2023 | 40,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Charles A. Rowland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 16 May 2023 | 40,000 | 70,000 (0%) | 0% | 1.1 | 43,200 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Charles A. Rowland | Director | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 16 May 2023 | 40,000 | 30,000 (0%) | 0% | 25 | 1,000,000 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Charles A. Rowland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Generation Bio Co | Charles A. Rowland | Director | Purchase of securities on an exchange or from another person at price $ 5.26 per share. | 19 Sep 2022 | 15,750 | 191,797 | - | 5.3 | 82,845 | Common Stock |
| Generation Bio Co | Charles A. Rowland | Director | Purchase of securities on an exchange or from another person at price $ 5.48 per share. | 15 Sep 2022 | 33,481 | 176,047 | - | 5.5 | 183,476 | Common Stock |
| Generation Bio Co | Charles A. Rowland | Director | Purchase of securities on an exchange or from another person at price $ 5.41 per share. | 15 Sep 2022 | 17,147 | 142,566 | - | 5.4 | 92,765 | Common Stock |
| Generation Bio Co | Charles A. Rowland | Director | Purchase of securities on an exchange or from another person at price $ 5.20 per share. | 13 Sep 2022 | 18,784 | 119,819 | - | 5.2 | 97,752 | Common Stock |
| Generation Bio Co | Charles A. Rowland | Director | Purchase of securities on an exchange or from another person at price $ 5.30 per share. | 13 Sep 2022 | 5,600 | 125,419 | - | 5.3 | 29,652 | Common Stock |
| Generation Bio Co | Charles A. Rowland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 19,200 | 19,200 | - | - | Stock Option (right to buy) | |
| Viking Therapeutics Inc | Charles A. Rowland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Generation Bio Co | Charles A. Rowland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Blueprint Medicines Corp | Charles A. Rowland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 4,500 | 4,500 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Charles A. Rowland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 2,250 | 5,812 (0%) | 0% | 0 | Common Stock |